Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
89 Cards in this Set
- Front
- Back
|
stavudine
|
d4T
Zerit NRTI |
|
|
Tenofovir
|
TDF
Viread NRTI |
|
|
Abacavir
|
ABC
Ziagen NRTI |
|
|
Lamivudine
|
3TC
Epivir NRTI |
|
|
Emtricitabine
|
FTC
Emtriva NRTI |
|
|
Didanosine
|
DDI
Videx NRTI |
|
|
Zidovudine
|
AZT/ZDV
Retrovir NRTI |
|
|
Nevirapine
|
NVP
Viramune NNRTI |
|
|
Efavirenz
|
EFV
Sustiva NNRTI |
|
|
Etravirine
|
ETV
Intelence NNRTI |
|
|
Delaviridine
|
DLV
Rescriptor NNRTI |
|
|
Fosamprenavir
|
FPV
Lexiva PI |
|
|
Atazanavir
|
ATV
Reyetaz PI |
|
|
Lopinavir/RTV
|
LPV/r
Kaletra PI |
|
|
Tipranavir
|
TPV
Aptivus PI |
|
|
Darunavir
|
DRV
Prezista PI |
|
|
Ritonavir
|
RTV
Norvir PI |
|
|
Indinavir
|
IDV
Crixivan PI |
|
|
Amprenavir
|
APV
Agenerase PI |
|
|
Nelfinavir
|
NFV
Viracept |
|
|
Saquinavir
|
SQV
Invirase PI |
|
|
Lamivudine + Zidovudine
|
Combivir
3TC + AZT dosed: bid |
|
|
Trizivir
|
AZT + 3TC + ABC --> BID
Zidovudine + Lamivudine + Abacavir |
|
|
Epzicom
|
ABC + 3TC --> QD
Abacavir + Lamivudine |
|
|
Truvada
|
TDF + FTC --> QD
Tenofovir + Emtricitabine |
|
|
Atripla
|
EFV + TDF + FTC --> QD (NNRT/NRTI)
Efavirenz + Tenofovir + Emtricitabine |
|
|
Enfuvirtide
|
Fuseon
T-20 Fusion Inhibitor |
|
|
Maraviroc
|
Selzentry
CCR5 Inhibitor |
|
|
things that increase transmission of hiv
|
- chronic illness
- std - viral load of the source person - length of exposure ( blood splash) amt of exposure ( vl of fluid) - males who are uncircumcized - hiv male having insertive anal intercourse w/ hiv + partner is alsho high risk -herpes |
|
|
hiv pathophysiology
|
1) binds
2) fusion 3) rt 4) integrase 5) transcription/translation 6) protease 7) glycosylation/assembly/release |
|
|
t cells cd4 receptors
|
ccr5
cxcr4 |
|
|
people who are homozygous deficient in ccr5 seem to be resistant to hiv infection
true/false |
true
|
|
|
people who are heterozygous in ccr5 appear to have a very delayed onset of hiv complications
|
true
|
|
|
the higher the viral loads, the faster the cd4 falls
t/f |
true
|
|
|
the lower the cd4, the higher the viral load will go
t/f |
true
|
|
|
cd4 count magic #`
|
200
|
|
|
cd4 count
when do patients start therapy |
when cd4 count < 200, do worse than those started w/ cd4>200
|
|
|
how to you diagnosis hiv
|
elisa
western blot -to confirm elisa |
|
|
test results mean
if negative... if postive.. |
negative= person was not infected w/ the virus prior to 6 mo ago
postive= person has antibodies to the virus |
|
|
if the ab are negative and the viral load is undectabable does the pt have hiv?
|
no
|
|
|
hiv aids surrogate markers
|
cd4
viral load |
|
|
aids dx
|
- hiv ab or hiv present in blood or tissue
and one of the following - cd4<200 -cd4%< 14 - aids defining illness |
|
|
what is the diffence b/t hiv and and aids dx
|
hiv= cd4<200, do elisa and wetern
aids - hiv ab or hiv present in blood or tissue and one of the following - cd4<200 -cd4%< 14 - aids defining illness |
|
|
nrti class wide se
|
lactic acidosis
lipoatrophy |
|
|
nrti
which drugs are common to cz lactic acidosis |
ddi/ didanosine/ videx
d4t /stavudine/zerit |
|
|
nrti
which drugs are common to cz lipoatrophy |
ddi/didanose/videx
d4t/stavudine/zerit |
|
|
diff b/t nrti vs nnrti
|
- nnrti
- do not bind to rt, prevent fxn of the enzyme - do not need to be triphosporylated - pk is not effected by intracellular vs extracellular concentraion - not as much mito toxicities |
|
|
nnrti class wide se
|
- rash
- changes in lft |
|
|
pi se
|
- gi (most common)
- hyperlipidemia - hypertriglyceridemia - hyperglycemia |
|
|
moa for fusion inhibitors
|
blocks the fusion of hiv ino the cd4 cell, thus preventing the infxn of new cells
|
|
|
stavudine cannot be combined w/
|
azt because of possible antagonism ( both are thymidine analogues) o
|
|
|
only nucleotide nrti analogue
|
tenofovir/TDF/ viread
|
|
|
bbw for tenofovir/viread/tdf
|
hep b flare if d/c tenofavir/tdf/viread
|
|
|
tenofavir ddi
|
ddI/didanoside/videx and tenofavir/vired/tdf, tdf inhibits the metabolism of ddi, inc ddi levels --> peripheral neuropathy, dec dose to 250 mg qd
|
|
|
abacavir/abc/ziagen adr
|
- hypersensitivity
- have to do hlab5701 testing before use to dx if predisponse to rxn |
|
|
abacavir/abc/ziagen mimic which nucleotide
|
guanine, only 1
|
|
|
lamivudine/3TC/epivir can be combined to cz synergy
|
lamivudine + zidovudine =combivir
|
|
|
bbw for emtricitabine
|
- bbw: hep B can flaire if tdf is d/cd its pts w/ chronic hep B
|
|
|
DDI needs to be dose adjusted when combined w/ what drug
|
Tenofavir/TDF/ Viread
|
|
|
azt se
|
-anemia
- bone marrow suppression/neutropenia - discolaration of nail beds |
|
|
can azt be given qd
|
no, cannot be give less often than bid bc lower gi wont absorb it
|
|
|
Whats in trizivir
|
azt/3tc/abc
|
|
|
whats in combivir
|
3TC & AZT
|
|
|
combivir and trizivir are dosed how?
|
bid bc of the azt component, any drug w/ azt has to be give bid
|
|
|
what in epzicom
|
abc/3tc
|
|
|
whats in truvada
|
tdf/ftc
|
|
|
epzicom
truvada which should you recommend more |
truvada bc have to do hla testing for epzicom bc of the abc content, hla test will dx if pt will become have hypersensitivity
|
|
|
nevirapine/nvp/viramune adr and bbw
|
adr: rash, tx w/ benadryl
-hepatitis--> hepatotoxic -bbw: men w/cd4 >400 women w/ cd4>250 |
|
|
fda dosing for nervirapine/nvp/viramune
|
bid
|
|
|
which nrti only has qd dosing
|
efavirenz/sustiva/efv
|
|
|
atripla contains
|
2 nrti and 1 nnrti
2nrti: tenofavir/emtricitabine 1 nnrti: efavirenz |
|
|
atripla is dosed
|
qd
|
|
|
indication for atripla
|
-new to tx, no prior resistance
- stable on current regimen w/out resistance |
|
|
atazanavir/atv/reyataz is dosed
|
qd, only pi to be dosed qd
|
|
|
se of atv/atazanavir/reyataz
|
- less negative effects on lipids, blood sugar and dirrhea
- hyperbilirubinemia |
|
|
which is the big gun pi
|
lopinavir/ritonavir/kaletra lpv/r
|
|
|
lopinavir/ritonavir/kaletra lpv/r se
|
- inc gi se
- inc lipids |
|
|
should all pi be boosted
|
yes
|
|
|
tipranavir cannot be used on what pts
|
naive
|
|
|
t/f ritonavir can be used monotherapy
|
no, ritonavir in hiv is used for pk effect, amt not high enough concentration to affect virus
|
|
|
ritonavir storage requirement
|
- needs refridgeration
|
|
|
ritonavir pk
|
- metabolized by p450: inhibits 3a4, poorly tolerated
|
|
|
indinavir/crixivan/idv se
|
kidney stones
|
|
|
nelfinavir
-se - pk properties |
- se: DIARRHEA!!!
- pk properties; pk propertie, cant be boosted, have to be taken w/ high fat meals, 1000 calories, |
|
|
why dnt we use saquinavir/invirase/sqv anymore
|
- bc only 4% absorption
|
|
|
enfuvirtide se
|
-injection site rxn
- inc in lft - have to reconsitute, hard to reconsitute a protein, cant shake it |
|
|
enfuvirtide/fuseon formulation
|
90 mg bid sq
|
|
|
maraviroc/selzentry is given how
|
orally admin
|
|
|
raltegravir (isentress) is what type of duge
|
integrase inhibitor
|
